The accomplished cardiologist has been on Cleveland Clinic’s staff since 2003, directing the cath lab and section of interventional cardiology and building a global reputation as a top clinical researcher.
RAS Inhibitors After TAVR Improve 1-Year Outcomes in Retrospective Cohort Study
A new analysis of the large TVT Registry provides the strongest evidence to date of a prognostic benefit from renin-angiotensin system inhibitor therapy following transcatheter aortic valve replacement.
Operational Efficiency in the Cardiac Cath Lab: The Time for Metrics Is at Hand
Can standardized metrics of efficiency in the cath lab improve the value of cath lab care? A new review paper makes the case with examples and a proposed set of nine metrics.
How Durable Are Bioprosthetic Surgical Aortic Valves?
The most comprehensive literature review of structural valve deterioration to date just took on this question. Although data were abundant, useful comparisons were few. The authors explain.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Transcatheter Valve Care: What to Watch For Beyond TAVR
Experts advise on developments to look for in the transcatheter space when it comes to managing diseases of the mitral, tricuspid and pulmonary valves.
3 Things to Keep an Eye on in Evolving TAVR Care
The next waves of progress in transcatheter aortic valve replacement are likely to involve expanding indications, valve refinements and new accessory treatments.
MitraClip Drives Down Deaths, HF Hospitalization in Secondary Mitral Regurgitation
The COAPT trial finds transcatheter mitral valve repair to be safe and highly effective in a setting with no good treatment options: symptomatic mitral regurgitation secondary to heart failure.
CMS Should Consider Quality, Not Just Quantity, for TAVR Coverage
Our experts outline their vision of ideal changes to the National Coverage Determination for programs performing transcatheter aortic valve replacement. A CMS decision is due in June 2019.
Transcatheter Valved Stent Tames Tricuspid Regurgitation in High-Risk Patients
The investigational GATE tricuspid valved stent is the first transcatheter prosthesis to be placed directly at the tricuspid annulus in humans. Our specialists who performed the first case discuss the technology’s evolution.
Watchman in the Real World: Reports on Use in High-Risk Patients and Overall Safety
Findings from three Cleveland Clinic real-world studies suggest a wider range of patients stand to benefit from the left atrial appendage closure device.